niacinamide has been researched along with Desmoid in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment." | 9.69 | A cost analysis of sorafenib for desmoid tumors. ( Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ, 2023) |
| "Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)." | 8.31 | Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023) |
| "After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib." | 7.77 | Activity of Sorafenib against desmoid tumor/deep fibromatosis. ( Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K, 2011) |
| "A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment." | 5.69 | A cost analysis of sorafenib for desmoid tumors. ( Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ, 2023) |
| "Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)." | 4.31 | Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023) |
| "After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib." | 3.77 | Activity of Sorafenib against desmoid tumor/deep fibromatosis. ( Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johns, MS | 1 |
| Merritt, WT | 1 |
| Rhodes, L | 1 |
| Ford, CN | 1 |
| Thompson, M | 1 |
| Lee, WM | 1 |
| Sheldon, Y | 1 |
| Petrelli, NJ | 1 |
| Tiesi, GJ | 1 |
| Garg, V | 1 |
| Gangadharaiah, BB | 1 |
| Rastogi, S | 1 |
| Upadhyay, A | 1 |
| Barwad, A | 1 |
| Dhamija, E | 1 |
| Gamangatti, S | 1 |
| Benech, N | 1 |
| Walter, T | 1 |
| Saurin, JC | 1 |
| Gounder, MM | 1 |
| Lefkowitz, RA | 1 |
| Keohan, ML | 1 |
| D'Adamo, DR | 1 |
| Hameed, M | 1 |
| Antonescu, CR | 1 |
| Singer, S | 1 |
| Stout, K | 1 |
| Ahn, L | 1 |
| Maki, RG | 1 |
1 trial available for niacinamide and Desmoid
| Article | Year |
|---|---|
A cost analysis of sorafenib for desmoid tumors.
Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea C | 2023 |
3 other studies available for niacinamide and Desmoid
| Article | Year |
|---|---|
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effec | 2023 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female | 2017 |
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance I | 2011 |